Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Marc Cerou"'
Autor:
Marc Cerou, Hoai‐Thu Thai, Laure Deyme, Sophie Fliscounakis‐Huynh, Emmanuelle Comets, Patrick Cohen, Sylvaine Cartot‐Cotton, Christine Veyrat‐Follet
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 6, Pp 941-953 (2024)
Abstract A joint modeling framework was developed using data from 75 patients of early amcenestrant phase I–II AMEERA‐1‐2 dose escalation and expansion cohorts. A semi‐mechanistic tumor growth inhibition (TGI) model was developed. It accounts
Externí odkaz:
https://doaj.org/article/7edf3331df7a41158673908d8fb6a32c
Autor:
Nadia Gaudel, Dorothée Semiond, Hoai-Thu Thai, Helgi van de Velde, Jean-Baptiste Fau, Geraldine Ayral, Christine Veyrat-Follet, Marc Cerou, Bernard Sebastien
Publikováno v:
British Journal of Clinical Pharmacology. 88:2052-2064
Aims Addition of isatuximab to pomalidomide/dexamethasone (Pd) significantly improved progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (RRMM). We aimed to characterize the relationship between serum M-protein kine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50cd516ab66a9b269559399607b5904e
https://doi.org/10.1111/bcp.15123
https://doi.org/10.1111/bcp.15123
Autor:
Dorothée Semiond, Hoai-Thu Thai, Bernard Sebastien, Helgi van de Velde, Nadia Gaudel-Dedieu, Marc Cerou, Christine Veyrat-Follet
Publikováno v:
Cancer Research. 81:1372-1372
Introduction: Isa is a CD38 monoclonal antibody with multiple modes of action for killing tumor cells. Isa, in combination with pomalidomide and dexamethasone (Pd), is approved for the treatment of adult pts with RRMM who have received ≥2 prior the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e786453e39c4f3d647a375c9c6237c73
https://doi.org/10.1158/1538-7445.am2021-1372
https://doi.org/10.1158/1538-7445.am2021-1372
Autor:
M. Fall, Muaamar Al-Gobari, Yanis Mimouni, Lutgarde Thijs, H. Le, François Gueyffier, Lars H Lindholm, Ivanny Marchant, Marc Cerou, Fabien Subtil, Behrouz Kassai
Publikováno v:
Journal of Hypertension. 35:2178-2184
To construct a sudden death risk score specifically for hypertension (HYSUD) patients with or without cardiovascular history.Data were collected from six randomized controlled trials of antihypertensive treatments with 8044 women and 17 604 men diffe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a8a2029ec7fcd19a0f83c1c5ff1b0c
https://doi.org/10.1097/hjh.0000000000001451
https://doi.org/10.1097/hjh.0000000000001451
Publikováno v:
AAPS Journal
AAPS Journal, 2020, 22 (1), pp.4. ⟨10.1208/s12248-019-0379-x⟩
AAPS Journal, American Association of Pharmaceutical Scientists, 2020, 22 (1), pp.4. ⟨10.1208/s12248-019-0379-x⟩
AAPS Journal, 2020, 22 (1), pp.4. ⟨10.1208/s12248-019-0379-x⟩
AAPS Journal, American Association of Pharmaceutical Scientists, 2020, 22 (1), pp.4. ⟨10.1208/s12248-019-0379-x⟩
International audience; INTRODUCTION:In this paper, we studied the effect over time of agomelatine, an antidepressant drug administered in patient with major depressive disorder, through item response theory (IRT), taking into account a strong placeb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e0662b51a194aff2865d1694b2080f0
https://doi.org/10.1208/s12248-019-0379-x
https://doi.org/10.1208/s12248-019-0379-x
Autor:
Helgi van de Velde, Nadia Gaudel-Dedieu, Marc Cerou, Christine Veyrat-Follet, Dorothée Semiond, Hoai-Thu Thai, Bernard Sebastien
Publikováno v:
Blood. 136:44-44
Background: Isatuximab (Isa) is a CD38 monoclonal antibody with multiple modes of action for killing tumor cells through direct tumor targeting and immune cell engagement (Moreno, Clin Cancer Res, 2019). The addition of Isa to pomalidomide (P) and de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81b9237199b3d7e876a3016d7fb4d60b
https://doi.org/10.1182/blood-2020-139358
https://doi.org/10.1182/blood-2020-139358
Autor:
Marc Cerou, Emilie Henin, Chao Chen, Alienor Berges, Claire Ambery, Tarjinder Sahota, Lia Liefaard, Stefano Zamuner
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology. 165(1)
A time-to-event (TTE) model has been developed to characterize a histopathology toxicity that can only be detected at the time of animal sacrifice. The model of choice was a hazard model with a Weibull distribution and dose was a significant covariat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b91a94b86ce3183ff4c30c42ef07a1e
https://pubmed.ncbi.nlm.nih.gov/29788384
https://pubmed.ncbi.nlm.nih.gov/29788384
Publikováno v:
Pharmaceutical Research
Pharmaceutical Research, 2018, 35 (2), pp.30. ⟨10.1007/s11095-017-2291-3⟩
Pharmaceutical Research, American Association of Pharmaceutical Scientists, 2018, 35 (2), pp.30. 〈10.1007/s11095-017-2291-3〉
Pharmaceutical Research, American Association of Pharmaceutical Scientists, 2018, 35 (2), pp.30. ⟨10.1007/s11095-017-2291-3⟩
Pharmaceutical Research, 2018, 35 (2), pp.30. ⟨10.1007/s11095-017-2291-3⟩
Pharmaceutical Research, American Association of Pharmaceutical Scientists, 2018, 35 (2), pp.30. 〈10.1007/s11095-017-2291-3〉
Pharmaceutical Research, American Association of Pharmaceutical Scientists, 2018, 35 (2), pp.30. ⟨10.1007/s11095-017-2291-3⟩
International audience; Purpose - Normalised prediction distribution errors (npde) are used to graphically and statistically evaluate mixed-effect models for continuous responses. In this study, our aim was to extend npde to time-to-event (TTE) model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e6d477ca183022145d302d52d49292e
https://www.hal.inserm.fr/inserm-01695500v2
https://www.hal.inserm.fr/inserm-01695500v2
